Efficacy of 177- Lutetium DOTATATE Peptide Receptor Radionuclide Therapy in patients with metastatic NENs and carcinoid syndrome refractory to somatostatin analogues

#3510

Introduction: Optimal management of refractory carcinoid syndrome (RCS) represents an unmet clinical need in patients with metastatic Neuro Endocrine Neoplasms (NEN).

Aim(s): This study assessed the efficacy of 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) in controlling CS refractory to conventional doses of Long-Acting SomatoStatin Analogues (LA-SSAs).

Materials and methods: All patients had progressive NEN and RCSand were 177Lu-PRRT naïve. LA-SSAs were continued during the 177Lu-PRRT without dose adjustments. Severity of flushing (0=nil to 4=severe), diarrhoea episodes/day and 24-hour urinary 5-Hydroxy-Indole-Acetic-Acid (u5HIAA) were assessed prior to the 1st and after the 4th cycle of 177Lu-PRRT. Radiological response was based on pre- and post-treatment cross-sectional images, whilst serum chromogranin A (CgA) levels were also measured. Progression Free Survival (PFS) was estimated from date of cycle 1 PRRT using the Kaplan-Meier method.

Conference:

Presenting Author: Ratnayake G

Authors: Ratnayake G, Koffas A, Theocharopoulos I, Hayes A, Navalkissoor S,

Keywords: carcinoid syndrome, PRRT,